Table 2: Baseline characteristics of the enrolled studies.

Study IDFasting glucose, mmol/LFasting insulin, mIU/LC-peptide, nmol/LHOMA-IRHbA1c, %TC, mmol/LTG, mmol/LHDL-c, mmol/LLDL-c, mmol/L

Ebert et al. (non-CD), 2014 [12]7.60/5.106.88/6.48NA2.70/1.30NA4.90/5.301.40/1.101.20/1.402.90/3.50
Ebert et al. (CD), 2014 [12]5.20/4.607.19/4.05NA1.40/0.80NA4.20/4.401.80/1.601.00/1.002.10/2.70
Fu et al., 2014 [11, 19]11.17/5.19NANANA9.20/NA4.62/4.562.26/1.641.17/1.352.83/2.54
Fenzl et al., 2014 [20]7.29/5.1910.06/10.081.09/1.023.72/2.727.72/5.735.48/3.951.96/1.371.33/1.733.22/2.55
Chen et al., 2015[14]8.70/4.906.81/4.31NA3.09/1.077.70/5.505.00/4.901.50/1.401.40/1.502.90/2.80
Espes et al., 2014 [21]8.50/6.20NA1.20/0.983.10/2.306.80/5.804.55/6.181.45/1.541.18/1.462.80/3.98
Hu et al., 2014 [15]9.99/5.068.27/7.16NANA9.23/5.265.14/4.612.46/1.591.16/1.273.28/2.80
Gómez-Ambrosi et al., 2014 [13]6.17/5.1723.70/12.901.19/0.746.30/3.00NA5.22/5.042.39/1.211.37/1.402.77/3.08
Yamada et al., 2015 [16]8.00/5.28NANANA8.8/5.25.40/5.152.16/1.901.16/1.423.39/3.28
Guo et al. (obese), 2015 [22]7.41/5.1621.00/16.582.84/3.086.91/3.937.59/5.564.95/5.162.10/1.890.96/1.243.01/3.22
Guo et al. (overweight), 2015 [22]9.09/5.3623.06/9.192.48/2.098.65/2.228.78/5.535.16/5.332.87/1.740.95/1.283.12/3.56
Guo et al. (lean), 2015 [22]9.33/5.089.04/6.631.67/1.413.81/1.519.56/5.164.62/4.822.45/1.121.07/1.332.53/3.21

CD: chronic hemodialysis; HDL-c: high-density lipoprotein-cholesterol; HOMA-IR: homeostasis model assessment of insulin resistance; LDL-c: low-density lipoprotein-cholesterol; NA: not available; TC: total cholesterol; TG: triglyceride.
All data are presented as mean variables of cases/mean variables of controls.